Sanctuary Advisors LLC Has $4.16 Million Position in Hims & Hers Health, Inc. $HIMS

Sanctuary Advisors LLC boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 16.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 128,116 shares of the company’s stock after buying an additional 18,443 shares during the quarter. Sanctuary Advisors LLC owned approximately 0.06% of Hims & Hers Health worth $4,160,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the period. Capital World Investors lifted its stake in shares of Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after purchasing an additional 223,892 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. State Street Corp lifted its stake in shares of Hims & Hers Health by 1.9% in the 3rd quarter. State Street Corp now owns 7,173,214 shares of the company’s stock valued at $406,865,000 after purchasing an additional 132,384 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after purchasing an additional 1,600,004 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20. Following the sale, the chief financial officer directly owned 262,954 shares of the company’s stock, valued at approximately $7,878,101.84. The trade was a 6.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the transaction, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. The trade was a 3.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 204,857 shares of company stock valued at $5,285,706 over the last three months. Company insiders own 13.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HIMS. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Needham & Company LLC raised Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research note on Monday, March 9th. Citigroup raised Hims & Hers Health from a “sell” rating to a “neutral” rating and upped their price target for the stock from $13.25 to $24.00 in a research note on Tuesday, March 10th. Finally, Leerink Partners upped their price target on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research note on Monday, March 16th. Four investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $32.53.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $27.27 on Friday. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The firm has a market capitalization of $6.22 billion, a P/E ratio of 53.47, a PEG ratio of 2.72 and a beta of 2.32. The business has a fifty day moving average price of $21.91 and a 200-day moving average price of $30.73.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same quarter last year, the business posted $0.11 earnings per share. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.56 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.